Navigation Links
Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman
Date:11/23/2009

CAMBRIDGE, Mass., Nov. 23 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced the appointment of pharmaceutical industry veteran Errol B. De Souza as Ligon's Executive Chairman of the Board.

"I'm very pleased to welcome Errol De Souza as Executive Chairman of the Board," said Patrick Kleyn, Ligon's chief executive officer and co-founder. He added, "Errol's breadth of experience in the life sciences industry -- particularly his leadership taking drug candidates from exploratory research through clinical development -- will be an asset to Ligon as we advance our current drug discovery campaigns targeting cancer and coagulations disorders, utilizing our proprietary small molecule microarray platform."

Dr. De Souza commented, "I look forward to chairing Ligon's Board, and contributing to the forward momentum being built by the company in discovering small molecule drugs against disease targets that others have found intractable. Ligon's unique and proprietary small molecule microarray technology offers compelling advantages, including broad applicability to all target classes, unprecedented scale of parallel screening, and minimal protein requirements. I believe Ligon has what it takes to leverage this already validated technology."

Errol B. De Souza, Ph.D. is a seasoned pharma and biotech industry leader with 20 years of experience in senior level Research & Development (R&D) and management positions at Aventis, Hoechst Marion Roussel (HMR), DuPont Merck, Neurocrine Biosciences, Synaptic Pharmaceuticals and Archemix. His R&D experience spans from leading large R&D organizations at DuPont Merck (Director of CNS Diseases Research), HMR (Senior Vice President and Head of Global Lead Generation) with worldwide responsibilities for chemistry, chemical development, biotechnology, high throughput screening and core research functions to Aventis (Senior Vice President and Site Head of US Drug Innovation and Approval) where he had worldwide responsibilities for managing the CNS, Immunology and Inflammatory Diseases pipeline as well as administrative responsibilities for the entire R&D organization in the US including the Global Drug Development Center.

Dr. De Souza's particular focus has been on the developing innovative approaches to accelerate progression of compounds from the candidate to clinical proof-of-concept stage and beyond through development of biomarker and pharmacogenomic strategies and utilization of imaging techniques. His experience on the biotech side spans from starting companies (Founder, Chief Scientific Officer and Executive Vice President of R&D at Neurocrine), to leading companies (President & CEO of Synaptic Pharmaceuticals and Archemix, Inc) and experience on several Boards of Directors and Scientific Advisory Boards of both public and private companies. In these capacities, he has successfully raised capital in both private and public environments and been involved in multiple collaborations with large pharmaceutical companies.

About Ligon Discovery

Ligon Discovery is a Harvard spinout that leverages a patented platform technology to identify pre-clinical drug candidates. The company's high-throughput microarray "chip" transforms the speed of the drug discovery process and expands the scope of new drug prospecting to include previously intractable targets. With funding from incTANK Ventures, the team has deployed the SMM technology, originally invented at Harvard University and further developed at the Broad Institute (founded by MIT and Harvard University) in Cambridge, and has established one of the largest small molecule screening capabilities in the industry. Using this facility, Ligon has successfully completed screens in the fields of coagulation and cancer, and is actively pursuing drug discovery in other areas of high unmet medical need. For more information, visit www.ligondiscovery.com.

SOURCE Ligon Discovery, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cambridge-based Ligon Discovery Raises $1M in Seed Funding
2. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
3. Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research
4. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
5. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
6. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
7. American Brain Tumor Association Calls for Discovery Research
8. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
9. International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
10. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
11. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
Breaking Medicine News(10 mins):